{"schema_version":"1","generated_at":"2026-10-29T09:19:43.873Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jasgit-sachdev","json_url":"https://www.findmykol.com/kol/jasgit-sachdev/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jasgit-sachdev","name":"Jasgit Sachdev","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Ideaya Biosciences","institution_url":"https://www.findmykol.com/institution/ideaya-biosciences","city":"Tempe","state":"AZ","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1770706632","orcid":"0000-0002-4408-7617","openalex":"A5055462512"},"summary":"Jasgit Sachdev is an Oncology physician affiliated with Ideaya Biosciences. OpenAlex indexes 228 publications with 8,811 citations (h-index 30); ClinicalTrials.gov lists 4 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":228,"cited_by_count":8811,"h_index":30,"latest_activity_year":2023,"source":"works"},"trials":{"count":4,"shown":3,"withheld":1,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05907954","title":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"IDEAYA Biosciences","source_url":"https://clinicaltrials.gov/study/NCT05907954","trial_url":"https://www.findmykol.com/trial/NCT05907954"},{"nct":"NCT04794699","title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","phase":"PHASE1","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"IDEAYA Biosciences","source_url":"https://clinicaltrials.gov/study/NCT04794699","trial_url":"https://www.findmykol.com/trial/NCT04794699"},{"nct":"NCT01567930","title":"Temsirolimus as Second-line Therapy in HCC","phase":"PHASE2","status":"UNKNOWN","role":"Overall official","sponsor":"University of Tennessee Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT01567930","trial_url":"https://www.findmykol.com/trial/NCT01567930"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":4,"shown":3,"withheld":1,"rows":[{"payer":"Foundation Medicine, Inc.","program_year":2022,"amount_usd":229,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1770706632"},{"payer":"Gilead Sciences, Inc.","program_year":2022,"amount_usd":35.69,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1770706632"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2021,"amount_usd":1370,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1770706632"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1770706632","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors","year":2023,"journal":"Investigational New Drugs","source_url":"https://doi.org/10.1007/s10637-023-01371-6","status":"verified"},{"title":"DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma","year":2023,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2023.03.013","status":"verified"},{"title":"Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors","year":2022,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-21-4363","status":"verified"},{"title":"First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors","year":2021,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-20-3757","status":"verified"},{"title":"Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial","year":2021,"journal":"Cancer Chemotherapy and Pharmacology","source_url":"https://doi.org/10.1007/s00280-021-04358-3","status":"verified"}],"source":"works"},"contact":{"address_1":"1931 E BRENTRUP DR","city":"Tempe","state":"AZ","zip":"852834926","phone":"901-605-6652","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1770706632","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":1,"payments":1,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2011-06-14","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}